ALSO NOTED: Nabi sells unit to Fresenius; Gene Logic to give Lilly drugs fresh look; La Jolla pulls European app;and much more.

> Nabi Biopharmaceuticals is selling a unit to Germany's Fresenius Medical Care for up to $85 million. Fresenius gains a new therapy for kidney failure. Report

> Eli Lilly has struck an innovative deal with Gene Logic to take a second look at its failed therapies. Gene Logic will analyze the drugs for other uses and stands to earn milestones and royalties for any approved products. Report

> La Jolla Pharmaceutical has pulled its European application for Riquent, saying that it wants to refile after gathering data from ongoing trials for presentation to the EMEA. Regulators had indicated to La Jolla that they would need more data for an approval. Release

> Belgium's Solvay and Wyeth have submitted an NDA to the FDA for their schizophrenia drug Bifeprunox. Report

> The FDA has granted orphan drug status to Anesiva's therapy for chronic foot pain. Report

> Nabi Biopharmaceuticals has completed enrollment for a mid-stage trial of NicVax, an experimental vaccine for nicotine addiction. Report

> Advocacy groups say a tentative settlement of a lawsuit against First DataBank could shave $4 billion off the price health plans pay for drugs. Report

And Finally… A California biotech company has closed shop after finding that the market for $32,000 cat clones is too small to survive on. Article

Suggested Articles

Biogen unveiled full phase 1/2 for a prospect that emerged from a shift in its thinking about treating amyotrophic lateral sclerosis.

It took a little longer than expected, but Biogen’s done it—along with partner Eisai, the Big Biotech has completed an FDA filing for aducanumab.

Gilead is ditching a new avenue of treating hepatitis B as it cuts ties with Precision Biosciences less than two years into their research pact.